These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36201195)

  • 21. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
    Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
    BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis.
    Diggikar S; Gurumoorthy P; Trif P; Mudura D; Nagesh NK; Galis R; Vinekar A; Kramer BW
    Front Pediatr; 2023; 11():1055813. PubMed ID: 37009271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study.
    Stahl A; Bründer MC; Lagrèze WA; Molnár FE; Barth T; Eter N; Guthoff R; Krohne TU; Pfeil JM;
    Acta Ophthalmol; 2022 Feb; 100(1):e91-e99. PubMed ID: 33742551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis.
    Kong Q; Ming WK; Mi XS
    BMJ Open; 2021 Feb; 11(2):e042384. PubMed ID: 33568373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comparison of Respiratory Outcomes after Treating Retinopathy of Prematurity with Laser Photocoagulation or Intravitreal Bevacizumab.
    Barry GP; Tauber KA; Greenberg S; Lajoie J; Afroze F; Oechsner H; Finucane E; Binenbaum G
    Ophthalmol Retina; 2020 Dec; 4(12):1202-1208. PubMed ID: 32512055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
    Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A
    Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.
    Stahl A; Lepore D; Fielder A; Fleck B; Reynolds JD; Chiang MF; Li J; Liew M; Maier R; Zhu Q; Marlow N
    Lancet; 2019 Oct; 394(10208):1551-1559. PubMed ID: 31522845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.
    Cheng Y; Zhu X; Linghu D; Liang J
    Acta Ophthalmol; 2020 Dec; 98(8):e1004-e1008. PubMed ID: 32385940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Retinopathy of Prematurity Regression and Reactivation Using an Artificial Intelligence-Based Vascular Severity Score.
    Eilts SK; Pfeil JM; Poschkamp B; Krohne TU; Eter N; Barth T; Guthoff R; Lagrèze W; Grundel M; Bründer MC; Busch M; Kalpathy-Cramer J; Chiang MF; Chan RVP; Coyner AS; Ostmo S; Campbell JP; Stahl A;
    JAMA Netw Open; 2023 Jan; 6(1):e2251512. PubMed ID: 36656578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aflibercept for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.
    Chen PJ; Rossin EJ; Vavvas DG
    Ophthalmic Surg Lasers Imaging Retina; 2021 Dec; 52(12):673-681. PubMed ID: 34908485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinopathy of prematurity.
    Jordan CO
    Pediatr Clin North Am; 2014 Jun; 61(3):567-77. PubMed ID: 24852153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.
    Zhu Y; Zhang T; Xu G; Peng L
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.
    Marlow N; Stahl A; Lepore D; Fielder A; Reynolds JD; Zhu Q; Weisberger A; Stiehl DP; Fleck B;
    Lancet Child Adolesc Health; 2021 Oct; 5(10):698-707. PubMed ID: 34391532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.
    Süren E; Özkaya D; Çetinkaya E; Kalaycı M; Yiğit K; Kücük MF; Erol MK
    Int Ophthalmol; 2022 Jun; 42(6):1905-1913. PubMed ID: 35094229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity.
    Cao JK; Han T; Tang HY; Zhang S; Wang ZH; Feng ZC; Li QP
    BMC Ophthalmol; 2023 Apr; 23(1):137. PubMed ID: 37016343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Supplemental oxygen for the treatment of prethreshold retinopathy of prematurity.
    Lloyd J; Askie L; Smith J; Tarnow-Mordi W
    Cochrane Database Syst Rev; 2003; 2003(2):CD003482. PubMed ID: 12804470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The severity and associated comorbidities of retinopathy of prematurity among micro-premature infants with birth weights less than 750 grams.
    Beck K; Young R; Read S; Harper H; Desireddi J; Harper CA
    J Neonatal Perinatal Med; 2019; 12(1):41-45. PubMed ID: 30400108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.